Skip Navigation
Skip to contents

JPMPH : Journal of Preventive Medicine and Public Health

OPEN ACCESS
SEARCH
Search

Author index

Page Path
HOME > Browse Articles > Author index
Search
Ji Yeob Choi 2 Articles
Erratum.
Sue K Park, Ji Yeob Choi
J Prev Med Public Health. 2010;43(1):96-97.
DOI: https://doi.org/10.3961/jpmph.2010.43.1.96
  • 3,005 View
  • 27 Download
AbstractAbstract PDF
There was an error in the numbering of the references in page 375-376: Sue K. Park, Ji-Yeob Choi. Risk Assessment and Pharmacogenomics in Molecular and Genomic Epidemiology. J Prev Med Public Health 2009; 42(6): 371-6.
Summary
Risk Assessment and Pharmacogenetics in Molecular and Genomic Epidemiology.
Sue K Park, Ji Yeob Choi
J Prev Med Public Health. 2009;42(6):371-376.
DOI: https://doi.org/10.3961/jpmph.2009.42.6.371
  • 5,142 View
  • 60 Download
  • 3 Crossref
AbstractAbstract PDF
In this article, we reviewed the literature on risk assessment (RA) models with and without molecular genomic markers and the current utility of the markers in the pharmacogenetic field. Epidemiological risk assessment is applied using statistical models and equations established from current scientific knowledge of risk and disease. Several papers have reported that traditional RA tools have significant limitations in decision-making in management strategies for individuals as predictions of diseases and disease progression are inaccurate. Recently, the model added information on the genetic susceptibility factors that are expected to be most responsible for differences in individual risk. On the continuum of health care, from diagnosis to treatment, pharmacogenetics has been developed based on the accumulated knowledge of human genomic variation involving drug distribution and metabolism and the target of action, which has the potential to facilitate personalized medicine that can avoid therapeutic failure and serious side effects. There are many challenges for the applicability of genomic information in a clinical setting. Current uses of genetic markers for managing drug therapy and issues in the development of a valid biomarker in pharmacogenetics are discussed.
Summary

Citations

Citations to this article as recorded by  
  • Selected LDLR and APOE Polymorphisms Affect Cognitive and Functional Response to Lipophilic Statins in Alzheimer’s Disease
    Fabricio Ferreira de Oliveira, Elizabeth Suchi Chen, Marilia Cardoso Smith, Paulo Henrique Ferreira Bertolucci
    Journal of Molecular Neuroscience.2020; 70(10): 1574.     CrossRef
  • Towards a personalized risk assessment for exposure of humans to toxic substances
    Thaís de Almeida Pedrete, Caroline de Lima Mota, Eline Simões Gonçalves, Josino Costa Moreira
    Cadernos Saúde Coletiva.2016; 24(2): 262.     CrossRef
  • Effect of genetic and environmental influences on cardiometabolic risk factors: a twin study
    György Jermendy, Tamás Horváth, Levente Littvay, Rita Steinbach, Ádám L Jermendy, Ádám D Tárnoki, Dávid L Tárnoki, Júlia Métneki, János Osztovits
    Cardiovascular Diabetology.2011; 10(1): 96.     CrossRef

JPMPH : Journal of Preventive Medicine and Public Health